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Abstract
Activation of inflammatory response during cardiopulmonary bypass (CPB) may lead to con-
siderable post-operative mortality. Recently, pentoxifylline (PTX), a methylxanthine derivative,
has been reported to be effective in inhibiting proinflammatory cytokine production. This study
aimed to determine whether or not PTX prevented CPB-induced systemic inflammatory response
syndrome (SIRS) in patients undergoing cardiovascular surgery. Thirty adult patients were ran-
domly separated into 2 experimental groups and 1 control group of 10 patients each. The experi-
mental group received peroral PTX administration (Group 1: 600 mg/day, Group 2: 900 mg/day),
while the control group did not. In Group 1 and Group 2, PTX administration was started on
preoperative day 5 and continued for 5 days. Serum levels of PTX and IL-6 were measured just
before and at 4 h after CPB using HPLC and ELISA, respectively. Respiratory index (RI) before
and at 4 h after CPB was calculated, and serum levels of C-reactive protein (CRP) and fibrinogen
on postoperative day 1 were also determined. There were no significant differences in age, body
weight, sex, surgical procedures, CPB time, haemodynamics or risk factors among the 3 groups.
Serum IL-6 level and RI index after CPB in Group 2 were significantly decreased compared with
those in Group 1 and the control group. These results, therefore, suggested that preoperative daily
administration of 900 mg/day PTX contributed to the attenuation of CPB-induced SIRS and had a
beneficial effect on the postoperative course after cardiovascular surgery.
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ardiac surgery and cardiopulmonary bypass 
(CPB) initiate a systemic inﬂ ammatory response 
syndrome (SIRS) that may lead to considerable post-
operative mortality as well as complications such as 
C
Activation of inﬂ ammatory response during cardiopulmonary bypass (CPB) may lead to considerable 
post-operative mortality.  Recently,  pentoxifylline (PTX),  a methylxanthine derivative,  has been 
reported to be eﬀ ective in inhibiting proinﬂ ammatory cytokine production.  This study aimed to deter-
mine whether or not PTX prevented CPB-induced systemic inﬂ ammatory response syndrome (SIRS) in 
patients undergoing cardiovascular surgery.  Thirty adult patients were randomly separated into 2 
experimental groups and 1 control group of 10 patients each.  The experimental group received per-
oral PTX administration (Group 1: 600 mg/day,  Group 2: 900 mg/day),  while the control group did 
not.  In Group 1 and Group 2,  PTX administration was started on preoperative day 5 and continued 
for 5 days.  Serum levels of PTX and IL-6 were measured just before and at 4 h after CPB using 
HPLC and ELISA,  respectively.  Respiratory index (RI) before and at 4 h after CPB was calculated,  
and serum levels of C-reactive protein (CRP) and ﬁ brinogen on postoperative day 1 were also deter-
mined.  There were no signiﬁ cant diﬀ erences in age,  body weight,  sex,  surgical procedures,  CPB 
time,  haemodynamics or risk factors among the 3 groups.  Serum IL-6 level and RI index after CPB in 
Group 2 were signiﬁ cantly decreased compared with those in Group 1 and the control group.  These 
results,  therefore,  suggested that preoperative daily administration of 900 mg/day PTX contributed to 
the attenuation of CPB-induced SIRS and had a beneﬁ cial eﬀ ect on the postoperative course after 
cardiovascular surgery.
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bleeding,  thromboembolism,  ﬂ uid retention and tem-
porary organ dysfunction.  This syndrome arises 
mainly due to contact between the blood and the arti-
ﬁ cial surfaces of the bypass circuit [1ﾝ3].  Attempts 
to prevent CPB-mediated inﬂ ammation by pharmaco-
logical means are warranted,  because a reduction in 
the inﬂ ammatory response may contribute to organ 
function protection and hence to improved recovery 
from surgical revascularization procedures,  particu-
larly in critically ill patients.  CPB-induced SIRS is 
characterized by the activation of complement,  mono-
cyte/macrophages and neutrophils,  and the release of 
cytokines and vasoactive substances [4,  5].  
Proinﬂ ammatory cytokines,  such as tumor necrosis 
factor (TNF)-ｸ,  interleukin (IL)-1ｹ and IL-6,  can be 
induced by a wide variety of stimuli and act on a large 
number of eﬀ ector cells [6,  7].  Thus,  their concen-
trations may reﬂ ect the status of the inﬂ ammatory 
response when multiple initiating processes are 
involved.
　 Previous clinical studies have demonstrated a 
marked increase in serum IL-6 postoperatively,  but 
have been unable to detect a consistent rise in serum 
TNF-ｸ and IL-1ｹ [8].  The failure to detect TNF-ｸ 
and IL-1ｹ in serum may be due to the transient,  local 
paracrine release of these agents and their rapid pro-
teolytic degradation [9].  Alternatively,  the assays 
may not be suﬃ  ciently sensitive,  or may fail to detect 
receptor-bound or protein-bound cytokines [10].  
These reports have suggested that the serum levels of 
IL-6 are the best parameter for assessing the status of 
the inﬂ ammatory response to surgical stress.  IL-6 is 
a pleiotropic cytokine involved in the regulation of 
immune responses and also plays an important role 
during acute-phase responses,  which include fever,  
corticosterone release and hepatic production of acute 
phase proteins.  This cytokine is produced by a variety 
of cells after some form of stimulation,  such as an 
infection,  trauma or immunological challenge,  which 
stimulates the release of immune-competent proteins,  
such as CRP from the liver and,  together with TNF-
ｸ and IL-1ｹ,  causes activation of T cells.  High serum 
IL-6 concentrations have been reported to be directly 
associated with mortality in patients with endotoxic 
shock [11,  12].
　 Furthermore,  proinﬂ ammatory cytokines appear to 
mediate many of the cellular events that contribute to 
injury after CPB.  Leukocytes are the main type of 
white blood cell involved in the inﬂ ammatory response,  
and their recruitment,  activation and cytotoxic eﬀ ects 
play a major role in the damage process.  The induc-
tion of inducible nitric oxide synthase (iNOS) has also 
been demonstrated in cardiovascular surgery with 
CPB [13,  14].  Nitric oxide (NO) is known to have 
cytotoxic eﬀ ects in various pathological con-
ditions; its major cytoprotective eﬀ ect is to inhibit 
leukocyte-endothelial cell adhesion [15,  16].  
Endothelial dysfunction with decreased NO levels has 
been implicated in ischemic-reperfusion injury [17].  
Intact endothelial function is essential to the mainte-
nance of an adequate vascular tone in order to prevent 
platelet aggregation in the intimal surface of blood 
vessels and to prevent smooth muscle proliferation 
[18].  Localized inﬂ ammatory reactions in the myo-
cardium are mainly caused by endothelial injury 
induced by ischemic reperfusion,  and CPB may exac-
erbate the resulting injuries through proinﬂ ammatory 
cytokine production.  Reducing proinﬂ ammatory cyto-
kine release may help to limit the CPB-induced SIRS.  
Reducing the invasiveness of cardiovascular surgery 
with CPB is therefore an issue of ongoing concern.
　 Pentoxyifylline (PTX),  a methylxanthine deriva-
tive,  known for many years for its hemorheological 
properties [19],  has proven to be a potent inhibitor 
of TNF-ｸ production by mononuclear cells [20,  21].  
PTX acts mainly by inhibiting phosphodiesterase,  
resulting in increased levels of cAMP [22].  PTX also 
reduces the production of interleukin-2 (IL-2) after the 
administration of OKT3 or lipopolysaccharide (LPS) 
in mice [23].  More recently,  it was shown that PTX 
preferentially suppressed murine TH1 cytokines with-
out aﬀ ecting TH2 cytokines,  and that this molecule 
can eﬃ  ciently suppress the development of autoimmune 
encephalomyelitis [24].  These reports suggested that 
PTX has the potential to attenuate the inﬂ ammatory 
responses that occur following CPB and that are asso-
ciated with signiﬁ cant postoperative hypoxemia and 
systemic release of neutrophil elastase and IL-6 [25].  
Iskesen I et al. indicated that PTX infusion during 
cardiac surgery inhibited the proinﬂ ammatory cytokine 
release caused by CPB [26].  In addition,  Ustunsoy 
H et al. showed that the addition of PTX to cardiople-
gic solution might help to avoid myocardial inﬂ amma-
tion and ischemic/reperfusion injury during open heart 
surgery [27].  Moreover,  Boldt J et al.  clearly dem-
onstrated that the use of PTX just after the induction 
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of anesthesia and continuing after CPB resulted in a 
reduced inﬂ ammatory response in comparison to an 
untreated control group [28].  However,  no reports 
have addressed whether or not prophylactic oral 
administration of PTX could attenuate CPB-induced 
SIRS.  Also,  no reports have clearly demonstrated a 
correlation between the anti-inﬂ ammatory eﬀ ect of 
PTX and respiratory function.
Patients and Methods
　 Patients requiring ﬁ rst-time coronary artery 
bypass grafting (CABG) were enrolled in the study.  
Thirty patients were randomly separated into 2 exper-
imental groups and one control group of 10 patients 
each.  The experimental groups received peroral 
Pentoxifylline (PTX) administration (Group 
1: 600 mg/day,  Group 2: 900 mg/day),  while the 
control group did not.  In the experimental groups,  
PTX administration was started on preoperative day 
5 and was continued for 5 days.  The exclusion criteria 
included recent myocardial infarction,  unstable angina,  
acute infection,  known immunological disease,  insulin-
dependent diabetes,  acute or chronic renal failure,  
redo surgery,  respiratory impairment and coagulopa-
thy.  The study protocol was approved by the Iwakuni 
Medical Center Trust Ethics Committee.  Written 
informed consent was obtained from all patients.
　 Blood samples were collected for serological assay 
just before the start of cardiopulmonary bypass (pre-
CPB) and at 4 h after the completion of CPB (post-
CPB).  The samples (10 ml) were collected in bottles 
containing EDTA and immediately placed in ice.  Each 
sample was then centrifuged at 1,500 g for 10 min,  
and the serum was collected into small Eppendorﬀ  
vials and frozen to －70 °C for later analysis.  Serum 
levels of pentoxifylline (PTX) were determined by 
high-performance liquid chromatography (HPLC) with 
solid-phase extraction,  and serum levels of IL-6 were 
quantiﬁ ed using an commercial enzyme-linked immuno-
sorbent assay (ELISA) kit (Quantikine,  R & D 
Systems,  Minneapolis,  MN,  USA).  Blood samples 
were also obtained on postoperative day 1,  and serum 
levels of C-reactive protein (CRP) and ﬁ brinogen were 
measured as appropriate.  The respiratory index (RI) 
was also determined in each group before the start of 
CPB and at 4 h after the completion of CPB.
　 Unless stated otherwise,  all data are expressed as 
the mean±standard error of the mean (SEM).  
Normally distributed parameters were analyzed using 
Student’s t test,  and p-values of 0.05 or less were 
considered statistically signiﬁ cant.
Results
　 Baseline patient demographics and clinical 
characteristics. Patient proﬁ les and pre-,  peri- 
and post-operative clinical data for each group of 
patients are listed in Table 1.  There were no signiﬁ -
cant diﬀ erences in age,  weight and sex among the 
groups.  In addition,  no statistically signiﬁ cant diﬀ er-
ences were found among the groups in the pre- and 
peri-operative haemodynamic data nor in the number 
of risk factors for cardiovascular surgery.  No statis-
tically signiﬁ cant diﬀ erences were observed among the 
groups in the post-operative CRP,  LDH and GPT 
values,  although all the values in Group 2 tended to be 
lower than those in the control group and Group 1.  
The peri-operative course and post-operative recovery 
periods were uneventful for patients in all 3 groups.
　 Serum PTX and IL-6 levels and RI index.
The serum PTX levels at pre-CPB in the control 
group,  Group 1 and Group 2 were 0,  351±68 and 
1255±153 ng/dl,  respectively.  The serum PTX lev-
els at post-CPB in the control group,  Group 1 and 
Group 2 were 0,  125±73,  and 813±179 ng/dl,  
respectively.
　 The serum IL-6 levels at pre-CPB in the control 
group,  Group 1 and Group 2 were 1.9±1.1,  3.3±
1.0 and 2.2±1.2 pg/ml,  respectively,  and no statisti-
cal signiﬁ cances were found in the IL-6 levels at pre-
CPB among the groups.  The serum IL-6 levels at 
post-CPB in the control group,  Group 1 and Group 2 
were 234±63,  181±96,  and 99±43 pg/dl,  
respectively.  The IL-6 level in Group 2 was signiﬁ -
cantly lower than that in the control group (p＜
0.01); however,  no statistically signiﬁ cant diﬀ erences 
were found in the IL-6 levels at post-CPB between the 
control group and Group 1,  and between Group 1 and 
Group 2.
　 The values of the RI index at pre-CPB in the con-
trol group,  Group 1 and Group 2 were 0.67±0.28,  
0.67±0.32 and 0.51±0.27 pg/ml,  respectively,  and 
no statistically signiﬁ cant diﬀ erences were found in the 
RI index at pre-CPB among the groups.  The values of 
the RI index at post-CPB in the control group,  Group 
71PTX Ameliorates  Respiratory DysfunctionApril 2008
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1 and Group 2 were 1.19±0.26,  0.71±0.40,  and 
0.57±0.33 pg/dl,  respectively.  The value of the RI 
index level in Group 2 was signiﬁ cantly lower than that 
in the control group (p＜0.05); however,  no statisti-
cally signiﬁ cant diﬀ erences were found in the RI index 
levels at post-CPB between the control group and 
Group 1,  and between Group 1 and Group 2 (Table 
2).
Discussion
　 PTX has been reported to be eﬀ ective in inhibiting 
TNF-ｸ production by mononuclear cells [20,  21].  
Recently,  various studies have demonstrated that the 
modulation of cytokine release induced by PTX is not 
restricted solely to TNF-ｸ.  In vitro studies showed 
that interleukin (IL)-1ｹ,  IL-6,  IL-2 and interferon-ｺ 
(IFN-ｺ) production could also be aﬀ ected by PTX 
[29].  In fact,  the present research clearly demon-
strated that preoperative oral administration of PTX 
(900 mg/day) yielded a signiﬁ cant reduction in the 
CPB-induced induction of proinﬂ ammatory cytokine 
IL-6,  which was consistent with the previous in vitro 
studies [20,  21].
　 As described above,  IL-6 plays an important role 
in the acute phase responses and the hepatic produc-
tion of acute phase proteins,  many of which are prote-
ase inhibitors [30].  IL-6 stimulates the release of 
immune-competent proteins,  such as CRP,  from the 
liver and,  together with TNF-ｸ and IL-1ｹ,  causes the 
activation of T cells.  High serum IL-6 concentrations 
have been reported to be directly associated with mor-
tality in patients with endotoxic shock or trauma.  
Various in vivo studies using antibodies against IL-6 
have shown conﬂ icting results regarding whether it 
plays a direct functional role in mediating tissue 
injury [31].
　 A previous study found IL-6 concentration to be 
correlated strongly with the concentration of CK-MB 
(an isoenzyme of creatine kinase with muscle and brain 
subunits) [32].  Our previous study also showed that 
the change in IL-6 concentration was signiﬁ cantly cor-
related with that in leukocyte elastase in patients 
undergoing coronary artery bypass grafting [33],  
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Table 1　 Patient proﬁ les
Control Group 1 Group 2
Patients 10 10 10
Age (y) 67.9±5.9 61.7±5.9 64.7±11.4
Weight (kg) 57.4±7.1 63.1±6.1 59.1±10.3
Sex (% male) 90.0 80.0 90.0
Pre-operative data
　Pp/Ps 0.21±0.04 0.17±0.04 0.22±0.07
　%VC 88.5±19.7 97.1±21.4 95.7±11.3
　FEV1.0 81.0±9.1 80.5±8.0 75.4±10.8
　Fibrinogen (mg/dl) 212.0±16.0 298.0±15.0 242.0±11.8
Peri-operative data
　No.  of grafts 2.9±1.2 3.1±0.9 3.2±1.4
　(1/2/3/4/5) (0/5/3/2/0) (3/4/3/0/0) (3/1/2/3/1)
　CPB time (min) 96.7±32.3 91.8±23.7 119.0±13.9
Post-operative data (POD 1)
　CRP (mg/dl) 5.2±1.0 4.5±0.6 4.4±0.8
　LDH (IU/l) 831.0±98.0 965.0±127.5 834.0±92.0
　GPT (IU/l) 23.0±3.2 27.6±5.7 20.1±7.3
P-values were considered not signiﬁ cant.
CPB,  cardiopulmonary bypass; CRP,  C-reactive protein; FEV, Forced expiratory volume; Pp/Ps, ratio of pulmonary artery pressure and 
systemic (systolic) pressure; VC, vital capacity.
Unless stated otherwise,  all data are expressed as mean±SD.
No statistical signiﬁ cances were observed between the groups.
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indicating that IL-6 is a critical mediator in inducing 
myocardial injury.  Neutrophil activation is an impor-
tant early step in ischemic-reperfusion injury,  and a 
greater degree of myocardial injury is seen after pro-
cedures associated with the increased production of 
IL-6,  suggesting that proinﬂ ammatory cytokine IL-6 
contributes to myocardial injury,  possibly by activat-
ing neutrophils [34,  35].
　 Our study showed no signiﬁ cant diﬀ erences in CRP 
concentration among the patients in the three groups,  
although the postoperative CRP level in patients 
receiving PTX administration tended to be lower than 
that in the control group.  The IL-6 level at post-CPB 
in patients receiving PTX (900 mg/day) was signiﬁ -
cantly lower than that in the control group,  which was 
consistent with the fact that the RI index level in 
Group 2 at post-CPB was signiﬁ cantly lower than that 
in the control group.  These results suggested that 
preoperative oral administration of PTX yielded a 
signiﬁ cant reduction in CPB-induced IL-6 induction,  
resulting in a decrease in postoperative CRP levels,  
followed by beneﬁ cial eﬀ ects on postoperative lung 
function.
　 Cytokines can act both individually and within a 
complex network of interrelated and interacting sig-
nals.  PTX,  which is highly active in the production of 
TNF-ｸ [20,  21],  a cytokine fundamental to the 
induction of the cytokine cascade,  is also obviously 
active in the synthesis of other cytokines,  particularly 
those with late expression,  such as IL-6,  which was 
also reconﬁ rmed in this clinical trial.  The same may 
be true for IFN-ｺ,  whose synthesis is stimulated by 
IL-2 which,  in turn,  is strongly inhibited by PTX 
[21,  27].  In addition,  PTX,  when administered to 
recipient animals,  attenuates reperfusion injury to a 
degree similar to that seen with leukocyte-depleted 
reperfusion [23],  suggesting that PTX could also 
decrease the systemic release of leukocyte elastase.
　 The neutrophil-mediated endothelium injury caused 
by ischemic reperfusion results in an increase in endo-
thelium permeability,  which leads to deterioration of 
gas exchange function in the lung,  and in a dysfunction 
in the production of the endothelium-dependent relax-
ant factor NO,  which contributes to an increase in 
pulmonary vascular resistance after reperfusion [36].  
In conclusion,  PTX prevented ischemic-reperfusion 
lung endothelium injury and improved post-ischemic-
reperfusion lung function by decreasing neutrophil 
lung sequestration.  This agent might be useful in pre-
venting lung injury in cardiac surgery using CPB.
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